Insmed Inc (NASDAQ: INSM)’s stock price has gone rise by 27.33 in comparison to its previous close of 70.68, however, the company has experienced a 23.15% increase in its stock price over the last five trading days. proactiveinvestors.com reported 2025-06-10 that Insmed Incorporated (NASDAQ:INSM) shares surged more than 27% after the company unveiled positive results from a Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The randomized, double-blind, placebo-controlled study met its primary endpoint as well as all secondary efficacy endpoints.
Is It Worth Investing in Insmed Inc (NASDAQ: INSM) Right Now?
Moreover, the 36-month beta value for INSM is 0.79. Analysts have varying opinions on the stock, with 13 analysts rating it as a “buy,” 6 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INSM is 177.29M and currently, short sellers hold a 9.29% of that float. On June 10, 2025, INSM’s average trading volume was 2.29M shares.
INSM’s Market Performance
INSM stock saw an increase of 23.15% in the past week, with a monthly gain of 38.29% and a quarterly increase of 22.12%. The volatility ratio for the week is 2.43%, and the volatility levels for the last 30 days are 2.35% for Insmed Inc (INSM). The simple moving average for the last 20 days is 28.43% for INSM’s stock, with a simple moving average of 23.09% for the last 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Jefferies repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Jefferies is $105 based on the research report published on May 13, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see INSM reach a price target of $100. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 25th, 2025.
Truist gave a rating of “Buy” to INSM, setting the target price at $48 in the report published on April 23rd of the previous year.
INSM Trading at 28.56% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 5.99% of gains for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Smith Michael Alexander, who sale 1,879 shares at the price of $73.50 back on Jun 05 ’25. After this action, Smith Michael Alexander now owns 67,718 shares of Insmed Inc, valued at $138,106 using the latest closing price.
Smith Michael Alexander, the Officer of Insmed Inc, proposed sale 1,879 shares at $73.47 during a trade that took place back on Jun 05 ’25, which means that Smith Michael Alexander is holding shares at $138,050 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.76 for the gross margin
The net margin for Insmed Inc stands at -2.66. The total capital return value is set at -0.56. Equity return is now at value -890.75, with -68.42 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 11.53. The interest coverage ratio of the stock is -10.72.
Currently, EBITDA for the company is -814.14 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 45.13. The receivables turnover for the company is 7.98for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.86.
Conclusion
To wrap up, the performance of Insmed Inc (INSM) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
